%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
95 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-02T13:23:06Z
2024-03-28T04:12:04-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T04:12:04-07:00
application/pdf
Heather
2004-89.mar
uuid:ef7db1f5-1dd1-11b2-0a00-3109277d8900
uuid:ef7db1f8-1dd1-11b2-0a00-d30000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
105 0 obj
[109 0 R]
endobj
106 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.46 77 m
558.47 77 l
S
0 0 0 0 k
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.3216 57.2343 Tm
(564)Tj
ET
0 0 0 0 k
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 423.8613 57.2343 Tm
(The Journal of Rheumatology 2005; 32:3)Tj
/T1_1 1 Tf
0.05659 Tw 10 0 0 10 52.968 736.1616 Tm
[(ing B cells produced anti-dsDNA)-251.8 (antibodies that were spe-)]TJ
0.0372 Tw 0 -1.18 TD
(cific for SLE)Tj
0 Tc 0 Tw 7.5 0 0 7.5 105.906 727.6617 Tm
(15)Tj
-0.00011 Tc 0.03729 Tw 10 0 0 10 113.406 724.3616 Tm
[(. )54.8 (As well, we reported that an increased pro-)]TJ
0.0161 Tw -6.0438 -1.18 Td
(portion of RP105-lacking B cells was also found in patients)Tj
0.22729 Tw T*
[(with Sj\232gren\325)54.8 (s syndrome and dermatomyositis)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 248.1336 704.0617 Tm
(4,16)Tj
-0.00011 Tc 0.2274 Tw 10 0 0 10 261.2586 700.7617 Tm
(, which)Tj
0.1785 Tw -20.8291 -1.18 Td
(are known to be characterized by B cell hyperactivation.)Tj
0.0219 Tw T*
(RP105-lacking B cells may include the subsets of autoreac-)Tj
0.02499 Tw T*
(tive B cells found in autoimmune diseases.)Tj
0.0863 Tw 1.2 -1.2 Td
(This assay plays a role in evaluation of activity of SLE)Tj
0.2431 Tw -1.2 -1.2 Td
[(with high sensitivity)64.8 (. )17.8 (The presence of increased RP105-)]TJ
0.04469 Tw 0 -1.2 TD
(lacking B cells suggested polyclonal B cell hyperactivation)Tj
0.2471 Tw T*
[(and hyper)17.7 (gammaglobulinemia. However)39.7 (, in our 2 cases,)]TJ
-0.00909 Tw T*
(serum IgG concentrations were within normal ranges. Our 2)Tj
0.242 Tw T*
(cases showed increased proportions of RP105-lacking B)Tj
0.11749 Tw T*
[(cells and negative tests for )54.8 (ANA. )17.7 (Therefore, the assay for)]TJ
0.0912 Tw T*
(RP105-lacking B cells may have been more sensitive than)Tj
-0.03461 Tw T*
[(serum IgG levels and )54.8 (ANA)-160.6 (in our 2 cases. In our preliminary)]TJ
0.0336 Tw T*
[(study)64.8 (, the presence of increased RP105-lacking B cells was)]TJ
-0.0081 Tw T*
(uncommon in inflammatory or infectious diseases including)Tj
0.0199 Tc 0.388 Tw T*
(tuberculosis and chronic hepatitis C virus infection.)Tj
-0.00011 Tc 0.01669 Tw T*
[(However)39.7 (, the precise specificity and sensitivity of the assay)]TJ
0.0593 Tw T*
(for RP105-lacking B cells in the diagnosis of SLE remains)Tj
0.02499 Tw T*
(an important issue.)Tj
0.13341 Tw 1.2 -1.2 Td
(Our cases were both men, which is unusual in SLE; it)Tj
0.11259 Tw -1.2 -1.2 Td
(will be necessary to accumulate cases and investigate fur-)Tj
-0.0127 Tw T*
[(ther the correlation of RP105-lacking B cells and )54.8 (ANA-neg-)]TJ
0.013 Tw T*
(ative SLE. Our Case 1 showed positive anti-Sm antibody in)Tj
0.0351 Tw T*
(the active phase of the disease. In general, positive anti-Sm)Tj
0.0495 Tw T*
[(and anti-dsDNA)-244.7 (antibody tests are not consistent with neg-)]TJ
0.02451 Tw T*
[(ative tests for )54.8 (ANA. However)39.7 (, Morris, )]TJ
/T1_0 1 Tf
[-0.4 (et al)]TJ
/T1_1 1 Tf
17.7884 0 Td
(have reported a)Tj
0.30659 Tw -17.7884 -1.2 Td
[(positive test for anti-dsDNA)-501.8 (antibody in )54.8 (ANA-negative)]TJ
-0.0002 Tc 0 Tw T*
(SLE)Tj
-0.04919 Tc 7.5 0 0 7.5 70.7439 380.6617 Tm
(11)Tj
-0.00011 Tc -0.02029 Tw 10 0 0 10 77.8752 377.3617 Tm
[(. )54.9 (Another report described positive anti-DNA)-174.8 (antibod-)]TJ
0.1759 Tw -2.4907 -1.2 Td
[(ies without )54.8 (ANA)-371.1 (in sera from SLE patients)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 237.1852 368.6617 Tm
(17)Tj
-0.00011 Tc 0.1759 Tw 10 0 0 10 244.6852 365.3617 Tm
[(. Moreover)39.7 (,)]TJ
0 Tw -19.1717 -1.2 Td
(Sugisaki, )Tj
/T1_0 1 Tf
0.0573 Tw 4.0016 0 Td
(et al)Tj
/T1_1 1 Tf
2.1141 0 Td
[(observed antiribosomal P)-270.5 (antibody in )54.8 (ANA-)]TJ
0.0797 Tw -6.1157 -1.2 Td
(negative SLE)Tj
0 Tc 0 Tw 7.5 0 0 7.5 107.9127 344.6617 Tm
(7)Tj
-0.00011 Tc 0.0797 Tw 10 0 0 10 111.6627 341.3617 Tm
[(. )54.9 (As well, a high prevalence of anti-Ro anti-)]TJ
-0.033 Tw -5.8695 -1.2 Td
(body and anti-La antibody has been reported in patients with)Tj
0.1185 Tw T*
(ANA-negative SLE)Tj
0 Tc 0 Tw 7.5 0 0 7.5 133.2864 320.6617 Tm
(8)Tj
-0.00011 Tc 0.1185 Tw 10 0 0 10 137.0364 317.3617 Tm
[(. )54.8 (Again, we have to accumulate cases)]TJ
0.037 Tw -8.4068 -1.2 Td
(and further investigate serological findings of positive anti-)Tj
0.02499 Tw T*
[(Sm antibody even in cases of )54.8 (ANA-negative SLE.)]TJ
0 Tc 0.00369 Tw 1.2 -1.2 Td
[(W)80 (e)0.1 ( describe 2 patients with )54.9 (ANA-negative SLE showing)]TJ
-0.00011 Tc 0.3185 Tw -1.2 -1.2 Td
[(increased concentrations of B cells lacking RP105. )54.8 (An)]TJ
0.021 Tw T*
(increased proportion of RP105-lacking B cells is associated)Tj
0.17171 Tw T*
[(with disease activity even in patients with )54.8 (ANA-negative)]TJ
0.0459 Tw T*
[(SLE. )54.8 (Analysis of expression of RP105 on B cells may be a)]TJ
0.12579 Tw T*
(sensitive method of evaluation of activity in patients with)Tj
0.09599 Tw T*
[(ANA-negative SLE; however)39.7 (, its significance in diagnosis)]TJ
0.02499 Tw T*
(is still open to debate.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
-0.0002 Tc -0.004 Tw 8 0 0 8 52.968 163.3617 Tm
[(W)79.8 (e)-0.1 ( thank Motoko Fujisaki for help in the description of the disease course\
.)]TJ
/T1_2 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 316.968 736.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 323.968 726.1616 Tm
[(1.)-875.1 (Maddison PJ, Provost )17.7 (TT)73.9 (, Reichlin M. Serological findings in)]TJ
1.675 -1.25 Td
(patients with \322ANA-negative\323 systemic lupus erythematosus.)Tj
0 -1.25 TD
(Medicine 1981;60:87-94.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Miyake K, Ogata H, Nagai )36.7 (Y)128.9 (,)-0.1 ( )54.8 (Akashi S, Kimoto M. Innate )]TJ
1.675 -1.25 Td
[(recognition of lipopolysaccharide by )17.7 (T)69.9 (oll-like receptor 4/MD-2 and)]TJ
0 Tc T*
(RP105/MD-1. J Endotoxin Res 2000;6:389-91.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Koarada S, )17.7 (T)69.9 (ada )36.8 (Y)128.9 (, Ushiyama O, et al. B cells lacking RP105, a)]TJ
1.675 -1.25 Td
[(novel B cell antigen, in systemic lupus erythematosus. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:2593-600.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Koarada S, )17.7 (T)69.9 (ada )36.8 (Y)128.9 (, Kikuchi )36.8 (Y)128.9 (, et al. CD180 \(RP105\) in rheumatic)]TJ
1.675 -1.25 Td
(diseases. Rheumatology Oxford 2001;40:1315-6.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 )54.8 (American College of)]TJ
1.675 -1.25 Td
(Rheumatology revised criteria for the classification of systemic)Tj
T*
[(lupus erythematosus. )54.8 (Arthritis Rheum 1982;25:1271-7.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Maraina CH, Kamaliah MD, Ishak M. )54.8 (ANA)-220.2 (negative \(Ro\) lupus)]TJ
1.675 -1.25 Td
[(erythematosus with multiple major or)17.7 (gan involvement: a case)]TJ
T*
[(report. )54.8 (Asian Pac J )54.8 (Aller)17.7 (gy Immunol 2002;20:279-82.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Sugisaki K, )17.7 (T)69.9 (akeda I, Kanno )17.7 (T)74 (, et al. )54.8 (An anti-nuclear )]TJ
1.675 -1.25 Td
(antibody-negative patient with systemic lupus erythematosus)Tj
T*
[(accompanied with anti-ribosomal P)-238.2 (antibody)64.8 (. Intern Med)]TJ
0 Tc 0 Tw T*
(2002;41:1047-51.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Reichlin M. )54.8 (ANA)-220.1 (negative systemic lupus erythematosus sera )]TJ
1.675 -1.25 Td
[(revisited serologically)64.9 (. Lupus 2000;9:1)36.8 (16-9.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Khajehdehi P)110.7 (, Islam SF)79.7 (, Salinas-Madrigal L, Bastani B. Lupus)]TJ
1.675 -1.25 Td
[(nephritis in an anti-nuclear antibody-negative young male. )17.7 (The)]TJ
T*
[(simultaneous presence of class III and class )17.7 (V)-257.2 (renal lesions. Clin)]TJ
T*
(Nephrol 1999;51:379-82.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Zoli )54.8 (A, )54.8 (Altomonte L, Galossi )54.8 (A, )17.7 (T)69.9 (aranto )54.8 (A, Mirone L, Magaro M.)]TJ
2.175 -1.25 Td
(Neurobehavioural and psychiatric manifestations in a case of )Tj
T*
(ANA-negative SLE with antiphospholipid antibodies. Clin)Tj
T*
(Rheumatol 1998;17:68-70.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Morris CN, Calobrisi SD, Matteson EL. )54.8 (Antinuclear antibody )]TJ
2.1381 -1.25 Td
(negative lupus associated with dystrophic calcification. )Tj
T*
(J Rheumatol 1998;25:825-6.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Blaustein DA, Blaustein SA. )54.8 (Antinuclear antibody negative sys-)]TJ
2.175 -1.25 Td
(temic lupus erythematosus presenting as bilateral facial paralysis. )Tj
T*
(J Rheumatol 1998;25:798-800.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Sircar S, )17.7 (T)69.9 (aneja )17.7 (V)128.9 (A, Kansra U. )54.8 (ANA-negative SLE presenting with)]TJ
2.175 -1.25 Td
(nephritis and oculomotor palsy \321 a case report. Indian J Pathol)Tj
T*
(Microbiol 1997;40:539-42.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Kimoto M, Nagasawa K, Miyake K. Role of )17.7 (TLR4/MD-2 and)]TJ
2.175 -1.25 Td
(RP105/MD-1 in innate recognition of lipopolysaccharide. Scand )Tj
T*
(J Infect Dis 2003;35:568-72.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Kikuchi )36.8 (Y)128.9 (, Koarada S, )17.7 (T)69.9 (ada )36.8 (Y)128.9 (, et al. RP105-lacking B cells from)]TJ
2.175 -1.25 Td
(lupus patients are responsible for the production of )Tj
T*
[(immunoglobulins and autoantibodies. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:3259-65.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Kikuchi )36.8 (Y)128.9 (, Koarada S, )17.7 (T)69.9 (ada )36.8 (Y)128.9 (, et al. Dif)17.7 (ference in B cell activation)]TJ
2.175 -1.25 Td
(between dermatomyositis and polymyositis: analysis of the )Tj
T*
[(expression of RP105 on peripheral blood B cells. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
[(2001;60:1)36.9 (137-40.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (McHardy KC, Horne CH, Rennie J. )54.8 (Antinuclear antibody-negative)]TJ
2.175 -1.25 Td
(systemic lupus erythematosus \321 how common? J Clin Pathol)Tj
0 Tc 0 Tw T*
[(1982;35:1)36.9 (1)36.9 (18-21.)]TJ
ET
0 0 0 0 k
/GS0 gs
104.13 82.08 407.5 -10.83 re
f*
0.5 w
104.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>stream
8;Z\7$Z6(j#j)%%j>tQR#eX#2F>TID6dq%J.e"M:1;EC@KXq4$[cmQmq>O\*/fttm
Siq?mjl^^E=?Qf3Y
AXhjg6kq3%o9E>`G/a,b+a)V8)C,6\9mofg:YZ^/_$OfH(g0%)l^@CJGc;SUGMjSoQXZ@l<30uh!n;cZ6.*P,JrN4R`s(>MDkaSg5d
qSVnb"=X[-QX*BnCf=C3T9Z)q#"R`e0l@Yls#h#1[+6ns>/IiR,18@>b?>)8fNc:,
3m"D.jaSNLM)\CnL_RRtV8Pk`F$QW#Jh;b;oJsK*?tAq<*ZgR"&_F3m1S)?qIC6.7
Rf$qD93ZqS[GNA0c\`K28?4;]%+k&\/RmV**ggO*_&M1$gAnc2+FVi
l!FL4@fMlSHNP$3Z`VS\nU`KMI:>\Ul%[*CIn_'Sn=%iaF0&<++>8bs&E=5NTH9j<
L)7(p.T]8g/$q)W=48;^(9CmEfLSScSeYt0**it-3o%n?J(B?NY:J$HX:%4\O5QiC
>c3+tc`7#'YZhD%M1C%oV>afWJ&&,:2nra'O&Q
\FdCKVmUeB
endstream
endobj
25 0 obj
[/Indexed/DeviceRGB 255 24 0 R]
endobj
24 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
48 0 obj
<>
endobj
50 0 obj
<>
endobj
64 0 obj
<>
endobj
88 0 obj
<>
endobj
100 0 obj
<>
endobj
63 0 obj
<>
endobj
79 0 obj
<>stream
H\T{Pgu4øguvS/F%X*`$/ "Y "yIT1'YwhNųRsB<+p+=k7#a_JERMZy۔)]
qR3DT Q7l$ƠYYwXt#pu|ktPTN5ǚgfZ7Q?ufɲzagvf>>ݺ֠_o6m$:+eӲ
z}ɤ_"gl>W}To|Zo[3F5;?ˠ_fIR-g͘nLXPJG1Vx[L)
K Q):C2RVnT4@(2W*@)SAocc|!da1$O5?1:)Ҥ<bɚ8l)fO.Uf)0aN,ߺ-7kObA(FC!If^H iHACy( Yl
)g;
l%yd1[JsDBQ4Fi0hն:J)}\hF !ǜ4IlN\KNjiHnMJiv]dߨGr$O05e]أRj4˯ N2̷29יWy$ѷ{B 3+u~o{aw;*oH/?;4s')npEh6nGL?hxm?i@k^ɀ3`@K 'roeO&s okxj
u
Q